Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy

Abstract

BackgroundCurrent treatment options for stage III non-small cell lung cancer (NSCLC) consist of different combinations of chemotherapy, surgery, radiotherapy and immunotherapy. Treatment choices are highly individual decisions, in which adverse events (AEs) are relevant for decision-making. This study aims to analyse reporting of AEs in prospective stage III NSCLC trials, focussing on trials including radiotherapy and/or surgery.MethodsPubMed was searched for prospective studies dealing with stage III NSCLC from January 1987 to April 2019. Meta-analyses were screened as a positive control. Pearson's Chi-squared test and smooth kernel distribution were used to estimate distributions. Data was resampled using bootstrapping.ResultsOut of 1193 initially identified studies, 119 met the inclusion criteria. Of these, 31 had a surgical procedure in any study arm. Grade 3 and 4 AEs were reported in 94.12% and 92.44% of the included studies, respectively. Reporting of grade 5 AEs was provided in 87.39% of cases. Grade 1 and 2 AEs were less commonly reported at 53.78% and 63.03%, respectively. One study did not mention any AEs. Of the 31 treatment arms including any form of surgery, AEs were not reported in 10. Overall, 231 different AE items were reported, only 18 of them were included in at least 20% of the analysed studies.ConclusionOverall, AE reporting in stage III NSCLC was inconsistent and inhomogeneous. Studies including surgical study arms often reported only treatment-related deaths in regards of surgical AEs. Underreporting of AEs prohibits the extraction of patient-relevant information for decision-making and represents a suboptimal use of invested resources.

Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists

“…Patient preference may be challenging in clinical practice as a multitude of emotions and biases influence shared decisionmaking (43,46). This process is even further complicated by the limited availability of patient-relevant informationsuch as detailed information from side effects from clinical trials in this setting (47). Potentially a third party acting as an intermediary between the specialists may be of value in providing an un-biased view (e.g., pneumologist or general practitioner).…”

Lanatoside C induces ferroptosis in non-small cell lung cancer in vivo and in vitro by regulating SLC7A11/GPX4 signaling pathway

“…Lung cancer is the most common and fast-growing malignant tumor in China ( 20 ). The high ability of cancer cells to invade and metastasize is the main reason limiting the improvement of survival after lung cancer surgery ( 21 , 22 ). Recent studies have found that lanatoside C has potential anti-tumor cell proliferation effects, and its anti-tumor mechanism mainly focuses on induction of autophagy, cell cycle arrest and induction of cell death, and has a good inhibitory effect on liver cancer and gastric cancer ( 18 , 19 , 23 ).…”

Management of stage IIIA NSCLC: the role of radiotherapy—a narrative review

“…It is essential to consider individual preferences while actively engaging in a shared decisionmaking process with the patient. While side effects are relevant for the decision-making of patients, unfortunately side-effect reporting has been rather poor in historical trials (48). Hopefully side effects and quality of life will be better recorded and reported in future trials.…”